Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status

Resistance to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, often related to Ras or secondary EGFR mutations, is a relevant clinical issue in Non-Small Cell Lung Cancer (NSCLC). Although Src TK has been involved in such resistance, clinical development of its inhibitors has bee...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Formisano, Luigi, D'Amato, Valentina, Servetto, Alberto, Brillante, Simona, Raimondo, Lucia, Di Mauro, Concetta, Marciano, Roberta, Orsini, Roberta Clara, Cosconati, Sandro, Randazzo, Antonio, Parsons, Sarah J., Montuori, Nunzia, Veneziani, Bianca Maria, De Placido, Sabino, Rosa, Roberta, Bianco, Roberto
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2015
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694888/
https://ncbi.nlm.nih.gov/pubmed/26325669
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados